Thrivent Financial for Lutherans
KNSA icon

Thrivent Financial for Lutherans’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Thrivent Financial for Lutherans’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,025
Closed -$155K – 2468
2023
Q2 		$155K Sell
11,025
-842
-7% -$11.3K ﹤0.01% 2419
2023
Q1 		$128K Hold
11,867
– – ﹤0.01% 2407
2022
Q4 		$178K Hold
11,867
– – ﹤0.01% 2366
2022
Q3 		$152K Buy
+11,867
New +$135K ﹤0.01% 2362

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Thrivent Financial for Lutherans's KNSA Position: Q3 2023 in Review

Thrivent Financial for Lutherans sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2023, closing a stake of 11,025 shares — an estimated $155K sold.

Thrivent Financial for Lutherans first reported a position in KNSA in Q3 2022 and held it in 4 quarters. The position peaked at $178K in Q4 2022. 134 funds tracked by Wall St. Rank hold KNSA as of Q3 2023.

  • Thrivent Financial for Lutherans reported no remaining Kiniksa Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 11,025 Kiniksa Pharmaceuticals shares in Q3 2023, an estimated $155K.
  • Thrivent Financial for Lutherans first reported a position in Kiniksa Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • Thrivent Financial for Lutherans's Kiniksa Pharmaceuticals position peaked at $178K in Q4 2022.
  • 134 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2023, filed 14 Nov 2023.